Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics and Merck Collaborate on Alzheimer s Studies

NEW YORK, July 28 (GenomeWeb News) - Celera Diagnostics said today that it has entered into an agreement with Merck to identify novel targets for drug discovery and diagnostic markers related to Alzheimer's disease.

 

Celera Diagnostics, a joint venture of Celera Genomics and Applied Biosystems, will conduct a functional genome scan to identify novel gene associations with Alzheimer's. Merck will receive rights for therapeutic applications, while Celera Diagnostics will retain the rights to diagnostic applications, Celera said.

 

Merck will also fund discovery research at Celera Diagnostics related to the project, and will make clinical milestone payments and pay a royalty on sales of potential commercial pharmaceutical products.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.